Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 1/20 | 0.53 |
| ▸ | TACR2 | P21452 | 3/20 | 0.46 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.43 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.43 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.43 |
| ▸ | LGALS7; LGALS7B | P47929 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 10/20 | 0.41 |
| ▸ | PTPN2 | P17706 | 5/20 | 0.41 |
| ▸ | PTPN11 | Q06124 | 5/20 | 0.41 |
| ▸ | CDC25B | P30305 | 8/20 | 0.41 |
| ▸ | PTPN6 | P29350 | 4/20 | 0.41 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23603344 | 1.00 | NT5E (0.53) | NT5ETACR2LGALS9LGALS1LGALS3 | |
| SCHEMBL13402395 | 0.98 | NT5E (0.53) | NT5ETACR2LGALS9LGALS1LGALS3 | |
| SCHEMBL3248483 | 0.96 | NT5E (0.56) | NT5ETACR2LGALS9LGALS1LGALS3 | |
| SCHEMBL24107840 | 0.96 | NT5E (0.56) | NT5ETACR2LGALS9LGALS1LGALS3 | |
| SCHEMBL13402397 | 0.94 | NT5E (0.56) | NT5ETACR2LGALS9LGALS1LGALS3 | |
| SCHEMBL27324965 | 0.92 | KMT2A (0.45) | NT5ETACR2LGALS9LGALS1LGALS3 | |
| SCHEMBL24107751 | 0.90 | NT5E (0.55) | NT5ETACR2PTPN1PTPN2PTPN11 | |
| SCHEMBL24672150 | 0.89 | NT5E (0.52) | NT5ETACR2LGALS9LGALS1LGALS3 | |
| SCHEMBL24107980 | 0.88 | SSTR4 (0.51) | NT5ETACR2LGALS9LGALS1LGALS3 | |
| SCHEMBL13857157 | 0.88 | NT5E (0.46) | NT5ETACR2LGALS9LGALS1LGALS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11479574-B2 | Vaccine against Klebsiella pneumoniae | IDORSIA PHARMACEUTICALS LTD (CH) | 2022-10-25 | — | — | US | disclosed |
| US-20210198304-A1 | VACCINE AGAINST KLEBSIELLA PNEUMONIAE | IDORSIA PHARMACEUTICALS LTD (CH) | 2021-07-01 | — | — | US | disclosed |
| EP-3492482-A1 | VACCINE AGAINST KLEBSIELLA PNEUMONIAE | Vaxxilon AG (CH) | 2019-06-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11479574-B2 | Vaccine against Klebsiella pneumoniae | SLC11A2, OSTC, STT3A | NT5E 3184/4885TACR2 3271/4885LGALS9 526/4885 |
| US-20210198304-A1 | VACCINE AGAINST KLEBSIELLA PNEUMONIAE | SLC11A2, OSTC, STT3A | NT5E 3184/4885TACR2 3271/4885LGALS9 526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.